U.S. News ranks Houston hospital No. 1 in Texas for 14th year in a row

Topping the Charts

Houston Methodist is once again the top hospital in Texas. Photo via Houston Methodist

U.S. News & World Report has released its 2025 rankings of the best hospitals in Texas, and they prove that Houston is in good hands.

The esteemed Houston Methodist Hospital was rated the No. 1 best hospital in Texas for the 14th consecutive year, and the No. 1 hospital in the metro area. Eleven more Houston-area hospitals earned spots among the statewide top 35.

U.S. News annually evaluates 581 Texas hospitals to determine which meet the publication's rigorous standards and offer the best care for patients. Hospitals are also ranked among 15 specialties, including cancer, cardiology, heart and vascular surgery, obstetrics and gynecology, orthopedics, psychiatry, rehabilitation, diabetes and endocrinology, and more.

Houston Methodist also appeared on U.S. News' prestigious list of Honor Roll hospitals, consisting of 20 medical centers that are deemed the "best of the best" hospitals in the nation. No other Texas hospitals made the list, further proving that Houston Methodist takes exceptional care of its patients.

"This is a tremendous achievement for our physicians and employees who dedicate themselves every day to our patients," said Marc Boom, M.D., president and CEO of Houston Methodist, in a press release. "We take pride in these national recognitions but more importantly, these accolades reflect our unparalleled commitment to keeping our patients at the center of everything we do."

Houston Methodist earned several top-20 rankings across 11 of the 15 total specialties nationwide. It also earned national recognition for having the 7th best gastroenterology/GI surgery program, the 8th best pulmonology and lung surgery programs, and the 10th best diabetes and endocrinology programs in the country.

Elsewhere in Houston, The University of Texas MD Anderson Cancer Center ranked as the No. 1 best cancer hospital in the nation for the 11th year in a row.

"We are honored to again be ranked as the nation’s top hospital for cancer care – a recognition that reaffirms our commitment to our shared mission to end cancer," said MD Anderson president Peter WT Pisters, M.D., in a release. "We are grateful to every one of our teammates, trainees, students, donors, volunteers, advocates and patients, whose unwavering dedication make it possible for MD Anderson to deliver outstanding patient care."

Other top-performing Houston-area hospitals that ranked among the best in Texas include:

No. 4 – Baylor St. Luke's Medical Center
No. 5 – Memorial Hermann Greater Heights Hospital
No. 6 – Memorial Hermann Hospital
No. 8 – Houston Methodist Sugar Land Hospital
No. 9 – Houston Methodist Willowbrook Hospital
No. 12 – Houston Methodist The Woodlands Hospital
No. 13 – Memorial Hermann Memorial City Medical Center (tied with Baylor Scott and White All Saints Medical Center - Fort Worth)
No. 21 – Houston Methdodist Baytown Hospital (tied with Methodist Hospital - Stone Oak in San Antonio and Texas Health Harris Methodist Hospital Fort Worth)
No. 25 – HCA Houston Healthcare Clear Lake in Webster (tied with St. Luke's Health - The Woodlands Hospital, Baylor Scott and White Medical Center - Round Rock-Lakeway, and Texas Health Presbyterian Hospital Plano)
No. 29 – University of Texas Medical Branch in Galveston (tied with Medical City Plano)

---

This article originally appeared on CultureMap.com.

From Your Site Articles

The merger that would have created the largest hospital system in Texas has been called off. Photo via memorialhermann.org

Major Texas hospital merger between Memorial Hermann and Baylor Scott & White called off

Discharged

Two Texas hospitals that were headed for union have called off their engagement plans, according to a joint statement. Dallas-based Baylor Scott and White and Houston-based Memorial Hermann announced in October that they were on track to combine forces following a letter of intent to merge and create a combined system.

The merger would have created a system with over 68 hospital campuses, 1,100 care delivery sites, almost 14,000 physicians, and serve almost 10 million patients each year, according to the October release. The more formalized agreement was expected this year.

"After months of thoughtful exploration, we have decided to discontinue talks of a merger between our two systems," the February 5 release states. "Ultimately, we have concluded that as strong, successful organizations, we are capable of achieving our visions for the future without merging at this time."

Jim Hinton, current CEO of Baylor Scott and White, was announced to be the system's CEO. Chuck Stokes, president and CEO of Memorial Hermann, was said to serve in the proposed office of the CEO, along with Baylor Scott and White president, Pete McCanna.

"We have a tremendous amount of respect for each other and remain committed to strengthening our communities, advancing the health of Texans and transforming the delivery of care," the release continues. "We will continue to seek opportunities for collaboration as two forward-thinking, mission-driven organizations."

This story will be updated as more information becomes available.

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

New Houston biotech co. lands $30M for pulmonary fibrosis drug

drug money

Most of us can claim a scar or two on our bodies. But when scarring develops inside the body, it’s known as a fibrotic disorder. A freshly launched Houston company, Oorja Bio Inc., is working on a treatment that can help to repair cells and reduce the damage wrought by the growth of fibrotic tissue in patients.

Late last month, Oorja Bio hit the scene with a pair of big announcements. Not only has the company raised a $30 million Series A thanks to founding investor California-based Westlake BioPartners, but it has also already paved the way for a Phase 2 study to take place this year.

Oorja Bio received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA), allowing the company to test its treatment in patients with idiopathic pulmonary fibrosis (IPF), a scarring of the lung tissue. IPF affects more than 150,000 adults in the United States and can result in a range of symptoms from shortness of breath to organ failure and death as it progresses.

Oorja Bio’s lead drug candidate, ORJ-001, was shown in a Phase 1 in-human trial to demonstrate “therapeutically relevant exposure and favorable tolerability” in 64 healthy adult volunteers in whom it was administered daily or weekly, according to a news release. Pre-clinical studies of ORJ-001 showed durable target tissue engagement and biomarker activity in bleomycin-induced lung fibrosis.

Administered subcutaneously, ORJ-001 is intended to improve and even restore function in cells that can reduce the signaling that causes IPF. It stops advancement of IPF and also allows for tissue repair. Currently available treatments for the disease can slow the development of IPF down, but do not address the declining lung function that’s inherent in its progression.

“The clinical and preclinical results from our studies to date give us confidence that ORJ-001 represents a novel treatment approach with the potential to repair and reverse fibrosis and modify disease progression in IPF,” Dr. Janethe Pena, CMO of Oorja Bio, said in the release.

“Our team is energized to deliver on our goal of redefining the future of fibrotic diseases, beginning with ORJ-001,” CEO and founder Sujay Kango added. “As we advance ORJ-001 in the clinic, we are embracing the paradigm shift in our biological understanding of IPF pathology that aligns with the central role of the alveolar epithelium. ORJ-001 was designed with this biology in mind and may provide, for the first time, a therapeutic intervention that repairs and reverses fibrosis and promotes disease modification.”

Most patients live only three to five years following their IPF diagnosis. Soon, ORJ-001 and Oorja Bio could give them a fighting chance.

Axiom Space tops $525M in oversubscribed round, announces Swiss subsidiary

funding boost

Axiom Space tacked on an additional $175 million to a previously announced capital raise, bringing the oversubscribed round to a total of more than $525 million.

Axiom shared in February that it had secured $350 million in a financing round led by Type One Ventures and Qatar Investment Authority. In the latest release from the company, Axiom reports that Japan-based MUFG Bank Ltd. joined the round as a new investor, in addition to continued participation from existing backers.

The funding will go toward developing the company's commercial space station, known as Axiom Station, and the production of its Axiom Extravehicular Mobility Unit (AxEMU) under its NASA spacesuit contract.

“Investor interest in this round outpaced what we set out to raise, which speaks to the moment we’re in,” Jonathan Cirtain, CEO and president of Axiom Space, said in the news release. “Our partners see what is possible in low-Earth orbit, and they see who is positioned to lead it.”

Axiom announced last month that it planned to open a Japanese subsidiary July 1. Earlier this week, it also shared plans to establish Axiom Space Switzerland, a wholly owned subsidiary based in Lucerne that is also expected to begin operations this summer.

The Switzerland subsidiary aims to establish Axiom's presence in Europe and help it partner with the European Space Agency and other space organizations and companies on the continent.

“Europe is a founding leader in the creation of the commercial space economy, and Switzerland is uniquely positioned to convene the government agencies, research institutions, and industrial entities that will shape its next decade,” Cirtain added in a separate release. “Axiom Space Switzerland facilitates the scaling of development and deployment of the infrastructure that will succeed the International Space Station.”

Texas cashes in among 10 best U.S. state economies in 2026 report

State Economics

A new study gauging the success or decline in economic performance in every state has revealed Texas' economy remains stable in 2026 after it dropped out of the top five to No. 8 last year.

Texas boasts the No. 8 best state economy in the U.S. this year, according to WalletHub's annual "Best & Worst State Economies" report. The personal finance website's analysts ranked all 50 states and the District of Columbia across 28 relevant metrics to measure each state's economic activity and health status, and its "innovation potential."

Notably, Texas leads the nation for the most exports per capita in the U.S. in a five-way tie with Louisiana, Kentucky, North Dakota, and Indiana. Across the study's three main categories, Texas ranked highly for its economic activity (No. 7) and economic health (No. 11), and the state's "innovation potential" rank is the 24th best in the nation.

This is how WalletHub ranked Texas' economic performance, where No. 1 is considered the best and No. 25 is considered average:

No. 6 – Change in non-farm payrolls
No. 8 – Change in GDP
No. 8 – Startup activity
No. 11 – Annual median household income
No. 18 – Government surplus/deficit per capita
No. 21 – Percentage of jobs in high-tech industries
No. 30 – Unemployment rate

WalletHub previously ranked Texas one of the top three states to start a business in 2026, with Houston earning its own entrepreneurial acclaim in separate rankings of the best big cities for new businesses and for starting a career.

"U.S. economic growth depends heavily on the performance of individual states, and some contribute more than others," the report's author wrote. "For example, California, Texas, New York and Florida have economies so large that if they were countries, they would rank in the top 20 in the world."

The five states with the worst state economies in 2026 are Rhode Island (No. 47), Maine (No. 48), Louisana (No. 49), Kentucky (No. 50), and West Virginia (No. 51).

The top 10 best state economies for 2026 are:

No. 1 – Massachusetts
No. 2 – Washington
No. 3 – Utah
No. 4 – California
No. 5 – Delaware
No. 6 – North Carolina
No. 7 – New York
No. 8 – Texas
No. 9 – Colorado
No. 10 – Florida

---